SCHEMBL7912422

SCHEMBL7912422

CC(NC(=O)C1(c2ccccc2)CCNCC1)c1cccnc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITGA4 P13612 3/20 0.51
ITGB7 P26010 3/20 0.51
ALDH1A1 P00352 1/20 0.45
CYP2C9 P11712 1/20 0.45
NAMPT P43490 1/20 0.45
ROCK2 O75116 1/20 0.45
AKT1 P31749 1/20 0.45
AKT2 P31751 1/20 0.45
AKT3 Q9Y243 1/20 0.45
KDM4E B2RXH2 1/20 0.44
HDAC1 Q13547 1/20 0.43
OPRM1 P35372 2/20 0.43
PIN1 Q13526 1/20 0.41
TP53 P04637 1/20 0.41
HTT P42858 1/20 0.41
KCNA5 P22460 3/20 0.41
TACR1 P25103 1/20 0.40
LMNA P02545 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
OPRD1 P41143 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3100018 0.88 ALDH1A1 (0.53) ALDH1A1HDAC1OPRM1TP53HTT
SCHEMBL7907628 0.80 NPC1 (0.51) ALDH1A1CYP2C9KDM4EHDAC1OPRM1
SCHEMBL13102482 0.80 NPC1 (0.51) ALDH1A1CYP2C9KDM4EHDAC1OPRM1
SCHEMBL13092152 0.80 TACR1 (0.49) ALDH1A1CYP2C9ROCK2AKT1AKT2
SCHEMBL7912225 0.80 ALDH1A1 (0.53) ALDH1A1ROCK2HDAC1OPRM1TP53
SCHEMBL5888338 0.80 PIN1 (0.50) ITGA4ITGB7ALDH1A1HDAC1PIN1
SCHEMBL6543233 0.79 ALDH1A1 (0.69) ALDH1A1ROCK2HDAC1OPRM1HTT
SCHEMBL7902182 0.76 ALDH1A1 (0.55) ITGA4ITGB7ALDH1A1ROCK2HDAC1
SCHEMBL13092262 0.76 ALDH1A1 (0.47) ITGA4ITGB7ALDH1A1CYP2C9PIN1
SCHEMBL2467934 0.75 C3AR1 (0.47) ITGA4ITGB7TP53TACR1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8324250-B2 Piperidine derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-12-04 US disclosed
US-8324250-B2 Piperidine derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-12-04 US disclosed
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-10-07 US disclosed
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-10-07 US disclosed
WO-2010106081-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2010-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HTR3A, OPRL1, OPRK1 ITGA4 691/4885ITGB7 1278/4885ALDH1A1 480/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.